Osteovision® ([F-18]-NaF)

[F-18]-Sodium Fluoride Injection, USP (“[F-18]-NaF”) is used in conjunction with Positron Emission Tomography (PET). Osteovision® enables physicians to non-invasively detect areas of altered osteogenesis associated with bone metastases. PET imaging centres throughout Canada trust CPDC for reliable, daily deliveries of F-18-based imaging agents.

Description

Supplied as a Sterile Solution for Injection at ≤ 11.1 GBq/mL at end of synthesis

Indications and Clinical Use

Osteovision ([F-18]-NaF Injection, USP) is indicated as an accessory to positron emission tomography (PET) for the detection of areas of altered osteogenesis associated with bone metastases.

Contraindications

None known. Please see the product monograph for more information, warnings and precautions.

Availability

Osteovision® will be available in the first quarter of 2019.

Canadian Product Monograph

English – Product Monograph

French – Monographie de Produit

For more information contact us at: